FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL.

Authors :: Gressin, R.
Daguindau, N.
Tempescul, A.
Moreau, A.
Carras, S.
Cartron, G.
Schmitt, A.
Houot, R.
Dartigeas, C.
Pignon, J.
Corm, S.
Bannos, A.
Mounier, C.
Dupuis, J.
Macro, M.
Fleury, J.
Jardin, F.
Karlin, L.
Damaj, G.
Feugier, P.
Source :: Hematological Oncology; Jun2017 Supplement, Vol. 35, p141-142, 2p
Publication Year :: 2017

Full Text Access

Tools